Genetic architecture and shared mechanisms of common 'neglected' diseases

Maik Pietzner[1,2,3], Spiros Denaxas[4,5,6,7], Summaira Yasmeen[1], Maria Wörheide[8], Hannah E. Schmidt[1], Burulça Uluvar[1], Aakash Nepal[1], Mine Koprulu[3], Julia Carrasco-Zanini[2,3], Matthias Arnold[8,9], Annika Vogt[10], Gabi Kastenmüller[8], Harry Hemingway[4,5,7,*], Claudia Langenberg[1,2,3,*]

[1]Computational Medicine, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
[2]Precision Healthcare Institute, Queen Mary University of London, London, UK
[3]MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
[4]Institute of Health Informatics, University College London, London, UK
[5]Health Data Research UK, London, UK
[6]British Heart Foundation Data Science Centre, London, UK
[7]National Institute of Health Research University College London Hospitals Biomedical Research Centre
[8]Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
[9]Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
[10]Department of Dermatology and Allergy, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
*these authors jointly supervised the work

Corresponding authors
Dr Maik Pietzner (maik.pietzner@bih-charite.de)
Prof Harry Hemingway (h.hemingway@ucl.ac.uk)
Prof Claudia Langenberg (claudia.langenberg@qmul.ac.uk)

ABSTRACT

Many diseases with significant health burden and healthcare costs have been neglected in biomedical research, partly due to a lack of data. Here, we systematically harmonized >12 million primary care and hospitalisation health records from ~440,000 UK Biobank participants into 1445 collated disease terms for genetic analyses. This included ~200 diseases with >10,000 cases that are predominantly managed in primary care, like skin and non-serious infectious diseases. We quantify the heritability for these common diseases, identify novel loci with extreme effect sizes, and highlight novel roles of poorly characterised genes, e.g. *PNLIPRP3* as a sebaceous gland cell-specific gene for rosacea. We characterise the substantial regional pleiotropy with more than 300 independent genomic regions associated with multiple, often seemingly unrelated diseases and use these insights to generate a pan-genome disease network of shared disease loci to prioritise potential pathways contributing to multiple diseases and onset of multimorbidity. We demonstrate the value of primary care data to improve and guide genetic approaches for drug selection, repurposing, and adverse event prediction, e.g., *IGFR1* as a putative multi-disease target for, among others, gout and atrial fibrillation, through network augmentation and integration of molecular quantitative trait loci. We make all results publicly available via an interactive webserver (https://www.omicscience.org/apps/phecodes). Our results provide new insights for diseases across diverse clinical specialties and provide a resource for drug discovery and mechanistic understanding.

INTRODUCTION

An inordinate amount of biomedical research and funding has been dedicated to conditions with high mortality and need for hospitalisations, largely neglecting hundreds of diseases that are less serious and predominantly managed in primary care, but that still pose a major burden for patients and the healthcare system[1,2]. Such common, but often understudied diseases further substantially contribute to one of the greatest health challenges in high- but also low- and middle-income countries, the increasing prevalence of multimorbidity[3].

Genome-wide association studies (GWAS) that examine associations between millions of human DNA sequence variants and (serious) diseases have transformed biomedical research over the past 15 years[4,5] and characterised the polygenic architecture of many complex diseases. They revealed novel disease pathways and drug candidates with support from human genetic studies are twice as likely to achieve final approval[6,7]. However, the common strategy of ever-increasing sample sizes for common traits and diseases now starts reaching saturation[8]. A greater translational potential will therefore lie in efforts that target patient populations that have been so far neglected, addressing common conditions mostly treated in primary care, as we recently demonstrated[9]. Such single disease efforts, however, need to be set into the context of an ever aging population that shifts demographics globally with many patients now presenting with not one but many diseases[3], that requires the development of novel treatment strategies. Biobank-scale studies that link deep characterization of participants with virtually complete health care trajectories through electronic health records (EHRs) only now provide the ability to systematically address this unmet medical need by generating a standardized set of disease definitions that captures the breadth of medical diagnosis and patient burden in a single cohort.

Here, we pooled EHRs for >440,000 participants of the UK Biobank (UKB) study from multiple data resources into 1445 medical disorder concepts ('phecodes'[10,11]) or 'diseases', with records from primary care more than doubling sample sizes for most conditions enabling first-ever GWAS for a number of diseases. We provide unique genetic insights that revealed unreported high-impact loci, novel risk genes for diseases predominantly managed in primary care, and extensive regional pleiotropy that links multiple, even seemingly unrelated diseases, providing potential pathways to multimorbidity. We finally demonstrate how our results can identify opportunities for drug repurposing and potential adverse effects of drugs on diseases currently missed.

RESULTS

Here, we describe the genetic architecture of 1445 diseases, based on medical disorder concepts[10,11] defined and collated from >12 million medical records from primary (general practice) and secondary care (hospital admissions and cancer registry), death certificates, and self-report among 441,671 white European UKB participants. For half of these diseases (50.1%, n=724), primary care was the only source of diagnosis data in more than 50% of participants (**Fig. 1**). Dermatological and (mild) infectious diseases showed the largest increase in sample size, with common conditions such as rosacea (n=25,307; 93.3% primary care) or acute sinusitis (n=58,140; 99.4% primary care) almost exclusively being identified through and managed in primary care (**Fig. 1 and Supplementary Tab. 1**).

For 363 diseases, common single nucleotide polymorphisms (SNPs) explained a significant ($p<3.5 \times 10^{-5}$) amount (median: 7.2%; IQR:4.1-9.0%) of the heritability, reaching values as high as 23.0% for retinoschisis or 9.0% for rosacea, illustrating a substantial heritable component of common, but not fatal conditions managed in primary care (**Supplementary Tab. 1**). We further observed little evidence of genomic inflation (median LDSC-intercept 1.01; IQR: 1.00-1.02) across 695 diseases with at least one genome-wide significant locus ($p<5 \times 10^{-8}$).

Figure 1 Distribution of case numbers. The *upper panel* displays the number of participants with one
of 1445 diseases considered. Diseases were grouped according to the chapters of the International
Classification of Diseases 10 (ICD-10) system. Within each chapter, diseases were ordered by case
numbers. The contribution of records only seen in primary care is indicated in orange. The y-axis has
been square root transformed to increase visibility. Selected diseases mostly (>50%) seen and
managed in primary care have been annotated with numbers in brackets indicating non-primary care
and primary care cases. The *middle panel* displays the proportion of cases for which primary care was
the only data resource. The *lower panel* displays the estimated single nucleotide polymorphism-based
heritability on the liability scale for diseases. Estimates are only shown if they passed multiple testing
correction (p<3.6x10^{-5}). The underlying data can be found in Supplementary Tab. 1.

Novel loci for common conditions

We identified 6188 genome-wide (GW) significant (p<5x10^{-8}) genetic variant – disease

associations, including 695 unique diseases (351 mostly recorded in primary care) and 4422

unique loci, through a combination of GWAS and Bayesian fine-mapping (**Fig. 2 and**

Supplementary Tab. 2, see **Methods**). About 16% (n=1028; including 251 at corrected GW-

significance) of all association pairs have not been reported so far (r^2<0.1) in the GWAS

catalog, of which two-thirds (n=673) are currently also missed by large biobank engines as

summarized in the Open Targets platform[12,13] (download 27/04/2022). For more than half of

the reported loci (n=2326; n=3542 genetic variant – disease pairs), we identified unreported

trait associations, whereas the remainder (n=1199; n=1555 genetic variant – disease pairs)

mapped to previously reported phenotype associations in the GWAS catalog[14] (download

27/04/2022). We replicated 80.1% (2053 out of 2560; directionally concordant and p<0.05)

of all identified variant – disease pairs with matching entries in the FinnGen release 8[15],

including 89 novel loci (**Supplementary Tab. 3**).

A very small fraction (0.5%, n=31 out of 6188) of all variant – disease associations showed

evidence of significant (p<8.7x10^{-6}) sex differences, with only three showing evidence for

sexual dimorphic effects (**Supplementary Fig. 3 and Tab. 4**). This included a stronger effect of

the low-frequent missense variant rs75495843 (MAF=3.0%; p.Ser460Leu within *PLCD1*) on the

risk for sebaceous cysts in women (OR: 3.17; 95%-CI: 3.03-3.30; p<1x10^{-300}) compared to men

(OR: 2.22; 95%-CI: 2.12-2.34; p<9.6x10^{-226}). The same missense variant has already been

demonstrated to cause hereditary trichilemmal cyst formation in a two-hit model, in which

the germline missense variant predisposes to or exaggerates the effect of somatic mutations

in *PLCD1*[16].

Figure 2 Summary of genome-wide association results across 1445 diseases. The *upper panel* displays
the number of associated diseases for each of 1104 independent genomic regions, with dot sizes

indicating the number of distinct ICD-10 chapters associated diseases belonged to. The most frequently prioritised effector genes are annotated for regions with ≥12 disease associations. The *middle panel* shows the genomic location of significant (p<5x10[-8]) genetic variants associated with at least one out of 724 diseases (y-axis) that are mostly recorded in primary care. The *lower panel* shows the genomic location of genetic variants associated with at least one disease that was recorded in multiple resources or resources other than primary care. Disease chapters are highlighted by background colours, whereas dot colours indicate whether the genetic variant has not been reported yet (r^2>0.1; black) or previously in the GWAS catalog or large-scale biobank engines (grey).

We fine-mapped more than half (n=377) of the unreported loci to ≤5 genetic variants in 95%-credible sets, including 186 with a single causal variant (**Supplementary Tab. 2**). This included low frequency variants (1%≤ minor allele frequency (MAF) <5%) with strong effects (|odds ratio (OR)| > 2.0) on 19 diseases including eight mainly seen in primary care. For example, rs145341070 (MAF=1.0%) increasing the risk for the inflammatory skin disease panniculitis by almost 15-fold (OR: 14.96; 95%-CI: 5.94-37.66; p< 9.4x10[-09], candidate gene: *MYEOV*) or rs138740163 (MAF=1.0%) increasing the risk for 'Mittelschmerz' (ovulation pain)[17] by more than 5-fold among women (OR: 6.00; 95%-CI: 3.18-11.30, p<3.02x10[-8], *RBM19*) with *RBM19* as a potential candidate gene already been linked to preimplantation development in animal models[18,19]. We further identified 96 rare (MAF<1%) variant – disease associations, of which 13 out of 15 imputed exonic variants were concordant with exome sequencing data available in UKB. This included a more than 50% decreased risk for polymyalgia rheumatica associated with the rare variant rs184097503 (MAF=0.4%; OR: 0.43, 95%-CI: 0.32-0.57, p<4.1x10[-9]). rs184097503 is in high LD (r^2=0.92) with the transthyretin stabilising missense variant rs28933981 (p.T139M) the effect of which is mimicked with Tafamidis in patients suffering from transthyretin amyloid cardiomyopathy[20]. These results illustrate strong locus-specific contributions to diseases that predominantly present in primary care.

Assigning novel effector genes for common conditions

To derive biologically, and possibly clinically, tangible insights, we systematically integrated functional annotations, gene[21] and protein[22] expression quantitative trait loci (QTL), an open-source machine-learning pipeline[13] as well as a biomedical knowledge graph[23] to map effector genes with high confidence (see **Methods**). We successfully assigned candidate causal genes for more than half of all genetic variant – disease associations (n=3271) with at least moderate evidence (candidate gene score ≥ 2), including 531 high-confidence assignments (candidate gene score ≥ 4; **Supplementary Tab. 2**). These gene sets provide a rich resource to improve

our understanding of common diseases typically seen and treated in primary care. For
example, genes associated with the inflammatory ear disease otitis externa were enriched
(FC: 95.5; p<7.2x10^{-5}) for members of the local control region (LCR)-associated chromatin
remodelling complex, responsible for the transcriptional regulation of the β-globin locus[24]
(**Supplementary Tab. 5**).

Among the loci with high-confidence gene assignments, ten were so far not reported. For
example, the common frameshift variant rs145843135 (MAF=5.4%, *PNLIPRP3*) was associated
with a reduced risk for rosacea (OR: 0.88; 95%-CI 0.85 - 0.92, p<4.9x10^{-10}) and further reduced
expression of *PNLIPRP3* in skin tissue from the GTEx project[21], with statistical colocalization
confirming a shared genetic signal with high confidence (posterior probability(PP) = 99.3%;
Fig. 3). *PNLIPRP3* encodes for pancreatic lipase-related protein 3 (PNLIPRP3) and is, despite
its name, highly expressed in skin[21,25]. More specifically, we observed that *PNLIPRP3* was
almost exclusively expressed in sebaceous cells (**Fig. 3**) that produce sebum, rich in
triglycerides, contributing to the integrity of the skin barrier. The exact function of PNLIPRP3
has not been shown so far, but it is predicted to have lipase activity, contributing to the
breakdown of triglycerides[26]. Reduced expression of *PNLIPRP3* in carriers of the risk allele,
and hence less activity of PNLIPRP3, may therefore alter sebum composition, but not
necessarily production, in line with a previous study in patients with papulopustular rosacea[27].
Another line of evidence for a role of lipid and intermediate metabolism in rosacea originated
from a common (MAF=45%) genetic signal at rs10882555 (OR: 0.90; 95%-CI: 0.9 - 0.92;
p<8.8x10^{-27}) likely tagging a missense variant (rs591157; r^2=0.94) in *C10orf129* encoding for
Acyl-CoA Synthetase Medium Chain Family Member 6 that has previously been shown to alter
plasma levels of 3-hydroxy-2-ethylpropionate, a break down product of leucine[28]. It remains
to be determined how altered sebum composition contributes to the chronic facial
inflammatory dermatosis characteristic for rosacea, but the protective, cell-type specific
effect of *PNLIPRP3* downregulation warrants further investigation as a putative non-steroidal
treatment option with putatively less adverse systemic effects.

Figure 3 *PNPLIPR3* is a sebaceous gland cell-specific risk gene for rosacea. A Regional association plot
for the risk of rosacea (top) and expression of *PNLIPRP3* in skin tissue (not sun exposed – middle; sun
exposed – lower) from the GTEx v8 project[21]. Numbers in brackets indicate posterior probabilities (PP)
of a shared genetic signal between gene expression and rosacea risk. Each genetic variant is coloured
according to its linkage disequilibrium with the lead risk variant rs145843135. Association statistics for
rosacea are based on logistic regression models from the present study, whereas association statistics
for *PNLIPRP3* were obtained from linear regression models published by the GTEx consortium. **B**
UMAP plot of epithelial cells based on single-nuclei RNA sequencing data from the GTEx project[29].
Different cell-types are coloured and annotated accordingly. **C** Gene expression of *PNLIPRP3* in the
same cell-types. A full version of PNLIPRP3 expression across various cell types can be found in
Supplementary Fig. 4.

Shared loci reveal molecular pathways of multimorbidity

Genomic regions that harbour multiple variants associated with multiple diseases can

highlight pathways underlying the co-occurrence of even seemingly unrelated diseases[3].

About a third (339 out of 1103) of all non-overlapping genomic regions outside the MHC

region included one or more clusters of genetic variants (r^2>0.8) associated with five or more

diseases (**Fig. 2**). This included extremely complex regions like chr1:150Mb, covering 58

genetic variants associated with 57 diseases across 11 chapters of the ICD-10 mapping to

highly pleiotropic genes like *FLG* or *IL6R* (**Fig. 4A**). Some regional association patterns were

only poorly explained by the size or complexity of the region, that is, number of contained

genes and independent variants (**Fig. 4A**). For example, a region on chromosome 9

(chr9:22Mb) centred around the cellular senescence genes *CDKN2A/CDKN2B* included 19

genetic variants associated with 33 diseases across six ICD-10 chapters, covering

cardiovascular, eye, skin, and metabolic diseases as well as cancers of different organs (**Fig.**

4B). While the locus has been described for the severe end of cardiovascular and metabolic

diseases, we observed in part opposing effect direction for primary care conditions like rectal

polyps but also a protective effect for cancers of the brain and skin (**Fig. 4B**).

To go beyond such regional pleiotropy, we partitioned the entire set of 756 loci associated

with at least two out of 371 diseases into 77 locus – disease clusters[30] (see **Methods** and

Supplementary Tab. 6), that is, diseases tightly linked by a shared set of genetic loci across

the genome. The network can also be explored interactively

(https://www.omicscience.org/apps/phecodes). Most clusters (n=57) contained diseases

belonging to at most two ICD-10 chapters with genes enriched for highly plausible pathways,

such as 'cardiac muscle contraction' for atrial fibrillation and arrhythmias, or 'bile acid

signalling' for non-malignant diseases of the exocrine pancreas and gall bladder

(**Supplementary Tab. 6**).

In contrast, clusters covering multiple organ systems can identify the interplay of pathways

determining multimorbidity. For example, patients that develop atopic dermatitis early in life

are known to be at high risk for other allergic diseases, most commonly asthma[31], but the role

of other inflammatory skin diseases is less clear. We identified a cluster including various

inflammatory skin diseases and asthma (**Fig. 4C**) that was enriched for genes involved in

leucocyte and T-cell activation, as well as other immune processes involving cytokine

signalling and T-cell differentiation (**Supplementary Tab. 6**). While loci shared between atopic

dermatitis and asthma were directionally concordant, only one out of four loci shared

between asthma and the inflammatory skin disease rosacea did so (**Fig. 4C**). Specifically, effect

directions for rs6498021 (OR_{asthma}: 0.95; 95%-CI: 0.93 - 0.96; $OR_{rosacea}$= 1.08; 95%-CI: 1.05 -

1.11; *IL21R*), rs115008099 (OR_{asthma}: 1.10; 95%-CI: 1.08 – 1.12; $OR_{rosacea}$: 0.89; 95%-CI: 0.87 –

0.91; *IL13;* **Fig. 3D**), and rs61816761 (OR_{asthma}:1.23; 95%-CI: 1.18 – 1.28; $OR_{rosacea}$: 0.82; 95%-

CI: 0.77 – 0.87; *FLG*) were in opposing directions. This suggests that unspecific inflammatory

stimuli (via *TLR1*) may increase the risk for both, asthma and rosacea, while genes modulating

T cell activation and differentiation via interleukins as well as maintenance of the skin barrier

(via *FLG*) distinguishes the aetiology of atopic dermatitis and rosacea, and eventually asthma.

In general, our results help to dissect the role of different, e.g., inflammatory, pathways to

inform the development of tailored treatment strategies for commonly co-occurring

conditions. This is of relevance when targeting shared disease mechanisms that likely operate

in opposing directions. For example, nine interleukin-13 antibodies are currently in clinical

trials, including for asthma, with atopic dermatitis, pruritis, dry skin, and erythema being

common side effects of drugs like Tralokinumab[32].

Figure 4 Regional and global pleiotropy of genetic loci. A For each of 1103 identified genomic regions,
excluding the MHC region, the width is shown against the number of associated diseases with at least
one variant in the respective region. Colouring was done based on the number of variant clusters
(r^2>0.8) and the size of the dots reflects the number of ICD-10 chapters the diseases belonged to.
Regions for which the number of associated diseases was poorly explained by region width, gene
density, or number of weakly independent signals are annotated with the gene most frequently
prioritized. **B** Regional association plot centred around *CDKN2A/CDKN2B* showing the minimum p-
value across all diseases named in the heatmap. P-values were derived from logistic regression
models. All lead, weakly independent variants in the region (r^2<0.8) are annotated and the heatmap
underneath displays transformed p-values and effect directions. Candidate causal genes are
highlighted in red and given next to lead variants. Variant – disease associations passing genome-wide
significance are indicated by black frames. **C** Subnetwork from a larger locus – disease network based

on global, e.g., across the genome, pleiotropy centred around asthma and skin diseases. This network
has been selected as one of 77 clusters in a bi-clustering approach. The entire network can be explored
interactively (https://omicscience.org/apps/phecodes/). **D** Same as B but centred around *IL13*.
279

COVID-19 and diseases mainly recorded in primary care

We next asked whether our results can help contextualize emerging diseases, namely COVID-

19, for which a high morbidity burden is an important risk factor for critical illness[33]. We

identified a total of 487 significant genetic correlations (r_G; false discovery rate (FDR) < 5%)

with at least one of 236 diseases (**Supplementary Tab. 7 and Fig. 5**) based on three different

COVID-19 outcomes provided by the COVID-19 Host Genetics Initiative[34]. More than half of

the genetically correlated diseases (n=129; 54.7%) are predominantly managed in primary

care, spanning a wide range of clinical specialties. For example, urticaria (r_G=0.37; $p<1.0\times10^{-5}$),

viral enteritis (r_G=0.31; $p<6.5\times10^{-3}$) and pyelonephritis (r_G=0.37; $p<7.5\times10^{-3}$), erectile

dysfunction (r_G=0.28; $p<2.2\times10^{-4}$), or gout (r_G=0.18; $p<5.7\times10^{-5}$) were significantly, although

moderately, correlated with critical illness following COVID-19 (**Supplementary Fig. 5 and**

Tab. 7). However, in Mendelian randomization (MR) analysis we did not obtain robust

evidence (FDR<5%) that any of the 162 significantly correlated diseases for which we had

sufficient genetic instruments was likely causative for any of the COVID-19 outcomes

(**Supplementary Tab. 7**). In contrast, we found evidence that genetic liability to all three

COVID-19 outcomes was significantly associated with viral pneumonia (e.g., critical illness:

beta=0.32; $p<7.3\times10^{-8}$) in a reverse MR setting (**Supplementary Tab. 7**). Even if not causal,

these results motivate to consider diseases predominantly managed in primary care in the

risk assessment for COVID-19, and our results can be immediately repurposed once large-

scale GWAS for post-acute sequelae of COVID-19[35] become available.

Drug repurposing and adverse effect prediction

To demonstrate the translational potential of our results, we next cross-referenced all

candidate causal genes with drug target annotations using the Open Targets platform[36], and

observed a 1.8-fold enrichment (409 out of 3088; $p<3.2\times10^{-21}$) of genes matching to drug

targets, in line with previous observations[6,7]. This included 136 gene-drug(s)-disease triplets

matching current clinical trials or approved medications, a number that almost tripled (n=387

gene-drug(s)-disease triplets) once we considered experimentally identified gene and protein

interaction partners[37]. This included well-known examples, such as RANKL inhibitors for

osteoporosis (via *TNFSF11*), potassium channel blockers for type 2 diabetes (via *KCNJ11*), or more recent developments like alpha-synuclein inhibitors for Parkinson's disease (e.g., NCT02459886; via *SCNA*) (**Supplementary Tab. 8**).

To identify potentially immediate examples to explore drug repurposing, we selected a total of 133 approved drugs (n=39 distinct loci) for which we 1) had matching GWAS evidence to establish effect directions of target modulation, and 2) observed additional diseases not yet indicated for the drug (**Supplementary Tab. 9** and https://omicscience.org/apps/phecodes/). While most newly suggested disease indications were similar to the established indication, we identified noteworthy exceptions. For example, the disease spectrum for Janus kinase (JAK) 2-inhibitors or TNF-alpha antibodies indicated for rheumatoid arthritis might be augmented to autoimmune thyroid disease (**Fig. 5**). In detail, variants likely tagging *IRF5* (rs142738614) and *STAT4* (rs11889341) were consistently associated with a higher risk for rheumatoid arthritis as well as hypothyroidism, and *STAT4* further with thyrotoxicosis. Both gene products act as transcription factors regulating the targets for JAK2-inhibitors and TNF-alpha antibodies (**Fig. 5**). The association between both variants and hypothyroidism persisted upon exclusion of patients with a history of thyrotoxicosis, while thyrotoxicosis was solely associated with the *STAT4* variant. This might suggest that while JAK2-inhibitors and TNF-alpha antibodies are candidates for repurposing for, likely autoimmune, hypothyroidism, only JAK2-inhibitors might be explored for autoimmune thyrotoxicosis such as Graves' disease. The co-occurrence of rheumatoid arthritis and autoimmune thyroid disease has long been recognized[38,39], with few, but suggestive reports that TNF-alpha inhibitors might improve thyroid autoimmunity in patients with rheumatic arthritis[40] and inhibition of TNF-alpha signalling in a mouse model ameliorated thyroiditis[41]. While we provide here genetically anchored evidence for targeted treatment strategies, the best timepoint for the treatment needs to be established in preclinical models and human trials as both medications might be most effective early in the disease process before much of the thyroid gland is damaged.

Figure 5 Evidence for repurposing of drugs indicated for rheumatoid arthritis for thyroid disease. A Stacked regional association plot centred around *STAT4* showing regional association statistics from logistic regression models for rheumatoid arthritis, hypothyroidism not elsewhere specified (NOS), and thyrotoxicosis with or without goitre. Each dot represents a single nucleotide polymorphism and those in high to moderate linkage disequilibrium (r^2) with the lead signal at the locus are colour in orange. **B** Same as **A** but centred around *IRF5*. **C** Odds ratios and 95%-confidence intervals for the two lead variants at each locus. *statistics for hypothyroidism NOS after excluding participants recorded for thyrotoxicosis with or without goitre. **D** Disease-gene-drug network displaying how JAK-2 inhibitors and TNF-alpha antibodies are linked to risk loci identified for rheumatoid arthritis and thyroid disease (light orange rectangles). Genes reported to interact with genes at risk loci are indicated by dotted lines and drugs were linked to target genes based on the Open Targets platform.

Molecular informed treatment options and adverse drug effects

To identify further opportunities for drug repurposing, to inform drug selection in early clinical trial phases, but also to predict potential adverse drug effects more systematically, we cross-

referenced expression of candidate causal genes or proteins (*cis*-acting) with strong evidence

of a shared genetic signal at risk loci (PP>80%) with recorded drug targets from Open

Targets[36]. We identified a total of 153 genes (n=142 by cis-eQTL; n=20 by cis-pQTL) across 133

diseases for which the product is the target of at least one out of 808 unique drugs

(**Supplementary Tab. 10**). These drugs segregated into three different categories when we

compared the genetically predicted effect of the target with the mechanism of action (MoA)

(**Supplementary Tab. 10 and 11**): 1) 353 drugs with a putative 'beneficial' effect, i.e., the

matching drug supposedly reverses the genetically predicted adverse effect of the target, 2)

302 drugs with putative 'harmful' effects, i.e., the drug might exaggerate the genetically

predicted mechanism, and 3) 153 drugs with both, putative 'beneficial' and 'adverse' effects.

The latter two highlighted hypothyroidism as a shared adverse effect for 53 drugs (10 targets),

including the well-described thyrotoxic effect of immune checkpoint inhibitors like

Ipilimumab[42].

Among the drugs with exclusively putative 'beneficial' effects in at least this study, were

multiple opportunities for drug repurposing for diseases mainly treated in primary care. For

example, the insulin-like growth factor I receptor (IGF1R) agonist Mecasermin might be

explored for the treatment of gout (*IGF1R* expression in heart left ventricle: PP=96.8%; OR

per 1 s.d. increase in gene expression: 0.75, 95%-CI: 0.69-0.81; p<3.24×10^{-12}; **Fig. 6**). A finding

also supported by a previous GWAS on serum urate[43], a biomarker for gout, candidate gene

studies[44], and more recently the Global Biobank Meta-Analysis Initiative[45,46]. We further

identified putative beneficial effects on the risk of atrial fibrillation (PP=96.1%; OR: 0.82, 95%-

CI: 0.78 – 0.88; p<2.7×10^{-10}), glomerular filtration (PP=96.6%; beta=1.61; p<7.3×10^{-8}), body

composition (e.g., hip circumference: PP=94.8; beta=-0.05; p<9.9×10^{-10}), and fasting glucose

levels (PP=99.0%; beta=-0.05; p<2.0×10^{-11}) in a phenome-wide colocalization screen. In

contrast, we observed little evidence for potential adverse effects, with haematocrit

(PP=98.2%; beta=0.05; p<7.9×10^{-10}) and red blood cell distribution width (PP=85.2%,

beta=0.05, p<1.1×10^{-8}) being the sole examples (**Supplementary Tab. 12**).

Low plasma glucose levels are a common side effect of Mecasermin[47] and a potential role of

IGF1R in type 2 diabetes more generally has been recently proposed[48]. There is further

evidence that the small molecule BGP-15, that stabilizes IGF1R, protects against experimental

models of atrial fibrillation in mice[49]. While these results demonstrate the translational

potential of integrating genetics with EHRs, they should be treated as preliminary and
evaluation in appropriate preclinical models is needed before human trials are considered.
385

Figure 6 Summary of molecular drug target prioritization. A Flowchart for the prioritization for drug
targets mapping to genetic risk loci in the present study. eQTL = expression quantitative trait loci; pQTL
= protein quantitative trait loci B Stacked regional association plot centred around *IGF1R*. Summary
statistics from logistic regression models for gout are from the present study and those for Atrial
fibrillation and fasting glucose have been obtained from the OpenGWAS database[50]. Gene expression
summary statistics were obtained from GTEx v8[21]. Colouring indicates linkage disequilibrium with the
lead cis-eQTL at the locus.
394

DISCUSSION

Despite their significant impact on patients' lives and healthcare expenses[2], numerous

common diseases predominantly managed in primary care have been largely neglected and

are underrepresented in biomedical research. We identified hundreds of genetic loci

associated with such diseases by harmonizing millions of EHRs towards a common set of

medical concepts and 1) demonstrated a substantial genetic control for most, in part driven

by strong single loci, 2) identified new diseases mechanisms, 3) showed the ubiquitous

presence of pleiotropy by which single loci or groups of loci are linked to multiple diseases or

multimorbidity, and 4) showcased how our results can guide treatment strategies by

highlighting opportunities for drug repurposing or to predict potentially adverse effects. We

created an interactive webserver (https://omicscience.org/apps/phecodes/) for fast

dissemination and exploration of our results to benefit the scientific community.

Most previous studies[51–53] focussed either on self-report or EHRs from secondary care to

perform GWAS with only few starting to explore the potential of primary care records[15]. This

focus on serious diseases is in stark contrast to the impaired quality of life patients with non-

serious diseases experience. For example, about 70% of patients with rosacea suffer from low

self-esteem and one-third reported stigmatization due to the persistent facial erythema and

flushing, that led them to reduce social contacts and they even missed work[54]. We confirm

known genetic causes of rosacea, like low-frequent variations in *STAT1*[55,56] (**Supplemental**

Tab. 2), provide new effector genes, like *PNLIPRP3*, and augment current concepts of how

toll-like receptors (TLR) contribute to the disease aetiology, with genetic support for TLR1

(**Supplemental Tab. 2**), but not TLR2[57]. These results clearly demonstrated the immense

potential of EHRs to immediately provide conceptual advances to understand the aetiology

of many common conditions managed in primary care. Such strong and distinct genetic

findings will also help to increase the recognition of diseases and medical conditions that

significantly impair patients' quality of life even without fatal consequences. However, the

medical concept ontology we used, phecodes, occasionally comprised a large set of often

diverse medical codes and more work on refined definitions is needed to transition from the

'phenome' to the 'diseasome'.

In an ever-aging population, most patient will develop not one but multiple diseases, so-called

multimorbidity[3], but it is currently unclear what drives multimorbidity, e.g., whether

commonly co-occurring conditions are genetically linked, and to what extend less severe

diseases contribute to the burden. We observed substantial pleiotropy at more than a third

of the genomic regions identified, with many genetic variants having effects on multiple

diseases, sometimes in opposing directions, that eventually revealed clusters of, sometimes

seemingly unrelated, diseases that seem to share common antecedents and might therefore

provide a mechanistic angle to understand and tackle the burden of multimorbidity.

Human genetic studies have now a pivotal role in the drug discovery process and we

replicated the enrichment of druggable targets among candidate causal genes[6,7] and further

provided support for multiple examples to explore drug repurposing. Most 'rediscoveries' did

thereby not relate to the candidate causal gene at the risk locus but rather indirectly via

protein – protein interaction networks, in line with recent observations[58,59]. State-of-the-art

genetic prediction tools, like MR, are not necessarily suited to formally support such

predictions, like JAK2-inhibitors for autoimmune thyroid disease, and we therefore anchored

such findings on shared disease aetiology instead. Our results can therefore provide a

resource for similar efforts incorporating GWAS summary statistics from large consortia with

higher power for less common outcomes. The same applies to the genetic prediction of

adverse events.

There are a few limitations that need to be considered when interpreting our results. First,

while we integrated multiple EHR resources that doubled the sample size for many outcomes

compared to previous studies, billing records do not represent clinical diagnosis and only

contextualization of genetic findings with disease biology, like gene expression in relevant

cell-types, can aid translation of our results. Second, our findings require replication in

independent and, importantly, ethnically diverse studies, which will hopefully be possible in

the near future. Third, we applied a GW-threshold to declare statistical significance that did

not take the number of diseases tested into account. While this may have increased the false-

positive rate, the replication rate of GW-significant loci is high in general[60] and our strategy

aligns with recent successful examples[15]. Most importantly it allowed us to provide first

biologically plausible and clinically relevant loci for diseases never looked at with still

comparatively small sample sizes given the population-based character of UK Biobank, and

further to investigate their role in a larger disease context based on genetic pleiotropy.

Fourth, studying rare (MAF<0.1%) genetic variation with putatively stronger effects will likely

reveal additional findings and potentially further support herein identified candidate causal

genes.

Our results demonstrate that integration of genetic data with billing information from EHRs,

including primary care, can yield biologically tangible and clinically relevant insights to

mitigate the health burden from common but often understudied diseases. We hope that our

results will serve as a resource to the wider research community to further accelerate the

development of much needed safe and effective treatments.

ACKNOWLEDGEMENT

The authors acknowledge the Scientific Computing of the IT Division at the Charité -

Universitätsmedizin Berlin for providing computational resources that have contributed to

the   research   results   reported   in   this   paper

(https://www.charite.de/en/research/research_support_services/research_infrastructure/s

cience_it/#c30646061). We want to acknowledge the participants and investigators of the

FinnGen study. M.K. is supported by Gates Cambridge Trust. J.C.-Z. is supported by a 4-year

Wellcome Trust PhD Studentship and the Cambridge Trust.

Data availability

All individual level data is publicly available to bona fide researchers from the UK Biobank

(https://www.ukbiobank.ac.uk/). This research has been conducted under the application

44448. GWAS summary statistics are available from the interactive webserver upon

publication (https://omicscience.org/apps/phecodes/).

Code availability

Associated code and scripts for the analysis will be made available upon publication.

Declaration of Interest

None of the authors have a conflict of interest.

Author contributions

Conceptualization: MP, HH, CL

Data curation/Software: MP, SD, MW, YS, AN, MA

Formal Analysis: MP, YS, HS, BU, MK

Methodology: MP, SD

Visualization: MP, BU

Funding acquisition: CL, HH

Project administration: CL, HH

Supervision: MP, CL, HH

Writing – original draft: MP, CL, HH

Writing – review & editing: SD, SY, MK, HS, JCZ, AV, GK

METHODS

Study population

UK Biobank (UKB) is a prospective cohort study from the UK, which contains more than 500,000 volunteers between 40 and 69 years of age at inclusion. The study design, sample characteristics and genome-wide genotype data have been described in Sudow *et al.*[61] and Bycroft *et al.*[62]. The UKB was approved by the National Research Ethics Service Committee Northwest Multi-Centre Haydock and all study procedures were performed in accordance with the World Medical Association Declaration of Helsinki ethical principles for medical research. We included 441,671 individuals in the genome-wide association analyses for whom inclusion criteria (given consent to further usage of the data, availability of genetic data and passed quality control of genetic data) applied.

Disease ascertainment

We collated electronic health records from primary and secondary care, cancer registries, and death certificates based on tables provided by UK Biobank (gp_clinical.txt, covid19_emis_gp_clinical.txt, covid19_tpp_gp_clinical.txt, hesin_diag.txt, death.txt) downloaded in June 2021. We parsed all records to exclude codes with a recorded date before or within the year of birth of the participant to minimize coding errors from EHRs. For each data set separately we generated mapping tables that link ICD-10, ICD-9, Read version 2, Clinical Terms Version 3 (CTV3) terms, or SNOMED-CT codes to a set of 1560 summarized clinical entities called phecodes[11,63] (**Supplementary Tab. 1**). For example, more than 90 ICD-10 codes can indicate participants with type 1 diabetes that are here collectively summarized under the phecode 'type 1 diabetes'[10]. We subsequently fused all data sources based on a common set of phecodes and retained for each participant and each phecode only the earliest entry across all EHR resources. We adjusted all analyses for assessment centre to account for regional differences in coding systems and case ascertainment. To increase the accessibility of our results, we used the term 'disease' instead of 'phecode' throughout the paper.

Genotyping, quality control and participant selection

Details on genotyping for UKBB have been reported in detail by Bycroft et al.[62]. Briefly, we used data from the 'v3' release of UKBB containing the full set of Haplotype Reference

Consortium (HRC) and 1000 Genomes imputed variants. We applied recommended sample

exclusions by UKBB including low quality control values, sex mismatch, and heterozygosity

outliers. We defined a subset of 'white European' ancestry by clustering participants based

on the first four genetic principal component derived from the genotyped data using a k-

means clustering approach with k=5. We classified all participants who belonged to the

largest cluster and self-identified as of being 'white,' 'British', 'Any other white background',

or 'Irish' as 'white European'. After application of quality control criteria and dropping

participants who have withdrawn their consent, a total of 444,441 UKBB participants were

available for analysis with genotype and phenotype data.

We used only called or imputed genotypes and short insertions/deletions (here commonly

referred to as SNPs for simplicity) with a minor allele frequency (MAF) > 0.001%, imputation

score >0.4 for common (MAF≥0.5%) and >0.9 for rare (MAF<0.5%), within Hardy-Weinberg

equilibrium ($p_{HWE}>10^{-15}$), and minor allele count (MAC) > 10. This left us with 15,519,342

autosomal and X-chromosomal variants for statistical analysis. GRCh37 was used as reference

genome assembly.

Confirming rare, imputed variants with whole exome sequencing data

To assess the quality of the assigned genotypes through imputation, we have examined the

correlation of overlapping rare variants with at least one significant disease association

between the imputed and whole exome sequencing (WES) data available over 200,000

individuals in UK Biobank (available from October 2020). For the comparison, we first lifted

over the positions of rare, imputed variants from b37 to b38 using LiftOver and converted the

SNP dosages of the imputed variants from bgen files to hard-call genotypes using plink v.2.

Subsequently, we have assessed the correlation of overlapping rare variants between the

imputed and WES data for 200,039 consented individuals. We have defined variants with

$r^2>0.8$ as concordant.

Genome-wide association studies

We performed genome-wide association studies (GWAS) for a total of 1,445 phecodes with

at least 80 cases (n>100 prior genetic exclusions) using REGENIE v2.2.4 via a two-step

procedure to account for population structure as described in detail elsewhere[64]. We used a

set of high-quality genotyped variants (MAF>1%, MAC>100, missingness <10%, $p_{HWE}>10^{-15}$) in

the first step for individual trait predictions using the leave one chromosome out (LOCO)

scheme. These predictions were used in the second step as offset to run logistic regression

models with saddle point approximation to account for case/control imbalance and rare

variant associations. Each model was adjusted for age, sex, genotyping batch, assessment

centre, and the first ten genetic principal components. We used a standard genome-wide

significance threshold to declare significant findings ($p < 5 \times 10^{-8}$). For diseases reported in only

one sex (n=113 in women, n=26 in men), we excluded the respective set from GWAS to avoid

inflation by inappropriate controls. In general, we included all participant with a disease in

their records as case and treated all other participants as controls to make best use of the

computational efficacy of REGENIE. Testing for reported SNPs showed highly consistent

results whether related diseases were included as controls rather than omitted. We used LD-

score regression to test for genomic inflation and calculated the SNP-based heritability (LDSC

v1.0.1)[65]. In the absence of general prevalence estimates across diseases, we used the

prevalence of diseases in UKBB to convert SNP-based heritability estimates to the liability

scale.

Signal selection and fine-mapping

We used regional clumping (±500kb) to select independent genomic regions associated with

each disease treating the extended MHC region as a whole (chr6:25.5-34.0Mb) and collapsed

neighbouring regions using BEDtools v1.5.

Within each region, apart from the MHC region, we performed statistical fine-mapping using

"Sum of single effects" model (SuSiE)[66] as implemented in the R package *susieR* (v.0.11.92).

Briefly, SuSiE employs a Bayesian framework for variable selection in a multiple regression

problem with the aim to identify sets of independent variants each of which likely contains

the true causally underlying genetic variant. We implemented the workflow using default

prior and parameter settings, apart from the minimum absolute correlation, which we set to

0.1. Since SuSiE is implemented in a linear regression framework, we used the GWAS

summary statistics with a matching correlation matrix of dosage genotypes instead of

individual level data to implement fine-mapping (*susie_rss()*) as recommended by the

authors[66]. We computed the correlation matrix with LDstore v1.0. In situations where SuSiE

did not deliver a credible set, we used the Wakefield approximation[67] to compute 95%-

credible sets.

We additionally performed sensitivity analyses by computing joint models for each locus –

disease combination, that is, we obtained all lead SNPs across the credible sets provided by

SuSiE and fitted one logistic regression model jointly modelling the effect of all distinct

credible sets in the locus. We subsequently retained only lead variants from each credible set

that reached genome-wide significance in either marginal or conditional statistics. We

implemented the logistic regression models in R v.4.1.2 using the *glm()* function and used only

unrelated white-European participants and the same adjustment set as described above.

We finally used LD-clumping (r^2>0.8) to identify credible sets shared across diseases.

Definition of unreported loci and previous associations

To define genetic loci that have not been reported so far, we first systematically checked

whether any of the identified variants or proxies (r^2>0.1) has already been reported in the

OpenTargets database[12] or the GWAS catalog[14] ([download: 27/04/2022](#)). We mapped

phecodes to EFO terms using ICD-10 and SNOMED-CT codes to define 'matching' phenotypic

entries.

Replication in FinnGen

In addition to a rigorous comparison to the GWAS catalog and other databases, we sought to

replicate our findings in the latest release from the FinnGen consortium[15] (release 8;

download 20/01/2023). We mapped phecodes to disease codes provided by FinnGen using

common ICD-10 codes and kept only GWAS summary statistics for diseases with at least half

the sample size in FinnGen (n=342,499) and for each mapping entry only the one with the

highest sample size. We note that due to different codes considered to group diseases, these

mappings should be regarded as approximate which may have lowered the success for

replication. After download, we lifted FinnGen statistics over to genome build 37 and

obtained summary statistics for a total of 2560 genetic variant – disease pairs with significant

marginal effects in UKB and approximately similar allele frequencies in both cohorts (≤20%

relative difference). We refer to concordant associations for all pairs with the same

association direction and at least nominal statistical significance (p<0.05) in FinnGen.

Sex-specific SNP effect

We tested for a potential modulating effect of sex on SNP – phecode association using an
additional interaction term in logistic regression models with the same adjustment set as
described above. We implemented this analysis in R v.4.1.2 using a set of 361,781 unrelated
white European individuals.

Candidate Causal Gene assignment

We used six different resources to provide candidate causal genes at each of the loci
identified.

1) Statistical colocalization with gene expression (cis-eQTL) in 49 tissues from the GTEx
632
633 project (v8)[21]. Briefly, we considered all protein coding genes or processed transcripts
634 encoded in a 1Mb window around risk loci and performed statistical colocalization[68]
635 to test for a shared genetic signal between a disease and gene expression. We adopted
636 a recently recommended prior setting[69] with $p_{12}=5\times10^{-6}$.

2) Statistical colocalization with plasma protein levels (cis-pQTL) from our previous
637
638 study[22] implemented in the same way as for eQTL.

3) Annotation of lead genetic variants and potential functional proxies ($r^2>0.6$) using the
639
640 Variant Effect Predictor software (version 106). We considered all genetic variants as
641 'functional' that had a score of twelve or lower based on the VEP recommendations
642 (https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html).

643 4) Nearest gene based on the gene body or transcription start site.

644 5) The Open Targets variant-to-gene pipeline[13].

6) A biomedical knowledge graph[23] that comprised multiple, often manually curated,
645
resources of gene – disease and other links. We assigned candidate genes based on
whether any of the ten nearest genes was no more than two nodes away from the
matching disease code ('phecode').

For each candidate gene at a locus, we computed a weighted score across all six criteria. We
divided colocalization evidence based on moderate (50%>PP<80%; 0.5 points) or high
(PP>80%; 1 point) confidence and functional variants were assigned highest priority (2
points). The final score is the sum across all criteria. We reported gene(s) with the highest
score as candidate causal gene(s) at each locus.

Visualising cell-type specific gene expression

We queried cell-type specific expression patterns for *PNLIPRP3* in the CELLxGENE browser[70]

and subsequently obtained the pre-processed Seurat from the solely single-nuclei RNA

sequencing study that showed expression levels of *PNPLIPRP3*. The study was based on eight

healthy organ donors from the GTEx project and contained a total of 209,126 cells[29]. We

imported the data into R using the Seurat package (v.4.0.0) and restricted the plotting to

epithelial and other cells of the skin to produce a Uniform Manifold Approximation and

Projection (UMAP) plot. We excluded alveolar, ciliated, and neuroendocrine cells from the

plot to increase visibility. The full UMAP plot is available as Supplementary Fig. 4.

Bi-clustering of locus – disease network

To identify highly connected co-clusters of loci and disease, we performed BiLouvain

clustering algorithm on a bipartite network. The bipartite network consisted of independent

sets of loci and diseases, thereby loci were connected to diseases through genome-wide

significant associations and diseases are only connected through shared loci. We used the

following settings to implement the BiLouvain algorithm[30]: cut-off for iterations = 0.01, cut-

off for phases = 0.0, order = 1, fuse = 0, CF = 0.0 and alpha = 1.0. The result of the clustering

had a Murata+ modularity score of 0.759. We used Cytoscape v3.9.0 to visualize the

network[71].

COVID-19 genetic correlation and Mendelian randomization

We downloaded GWAS summary statistics for three different endpoints related to COVID-19

(A2 – critical illness; B2 – hospitalisation; C2 – SarsCov-2 infection) provided by the COVID-19

Host Genetics Initiative (release 7)[34]. We used summary statistics excluding UK Biobank to

avoid sample overlap. We computed genetic correlations as implemented by LD-score

regression (LDSC v1.0.1)[65] with precomputed LD-scores, excluding the extended MHC region.

To test for potentially causal associations of phecodes onto COVID-19, we used genetic

instruments identified in the present study for a total of 176 phecodes with at least five

genetic variants in a two-sample MR setting. We used MR-PRESSO[72] as a first line tool as

previously suggested[73] to account for possible pleiotropy and subsequently report effect

estimates from inverse-variance weighted analysis as the primary results. We flagged MR

results that showed signs of heterogeneity across instruments using Cochran Q statistic.

Conversely, we obtained regional lead variants ($p < 5 \times 10^{-8}$; 1Mb window) across all three

COVID-19 outcomes to test for a putative causal effect of genetic liability towards COVID-19

and 850 phecodes with at least 1000 cases. We excluded any variants mapping to the MHC

regions for all analysis and implemented MR using the R packages *MendelianRandomization*

(v0.6.0)[74] and *TwoSampleMR* (v0.5.6)[75].

Drug target annotation

To identify putative druggable targets and test for evidence for drugs already in clinical trials,

we queried the Open Target database[36] for all genes likely linked to GWAS loci based on our

candidate causal gene assignment. We augmented this gene list by functionally validated

interaction partners from the SIGNOR network[37] and retained all matching drugs for further

investigation. We further mapped phecodes to different disease ontologies to obtain drugs

already in clinical trials and to define indication matchings.

To provide evidence whether a drug might be beneficial or harmful based on genetic

predictions, we compared genetically predicted effect estimates based on Wald ratios

between colocalising (PP>80%) gene/proteins and phecodes with mechanisms of action again

obtained from the Open Targets database.

Phenome-wide colocalization screen at IGF1R

To explore potential effects of genetic variation affecting gene expression of *IGF1R* beyond

gout, we obtained corresponding summary statistics (±250kb around the gene body) for the

expression in left ventricle of the heart (positive colocalization results for gout) from GTEx

v8[21]. We then queried the lead variant (rs6598541) and proxies in strong LD (r^2>0.8; based on

UK Biobank) using the OpenGWAS database[50] to identify all associations with $p<10^{-5}$. For all

49 traits meeting this criterion, we performed statistical colocalization as described above.

Since some anthropometric traits harboured multiple independent signals in the region,

violating the single causal variant assumption, we further used a more recent development

of colocalization[76] that first uses SuSiE to fine-map[77] each trait and afterwards performs

colocalization among all possible credible sets. We used the same LD-backbone as described

in the fine-mapping section and further restricted the maximum number of credible sets to

five and pruned correlated credible sets if needed (r^2>0.2). We eventually used the Wald ratio

to provide an estimate about the effect of increasing *IGF1R* expression by 1 s.d. on all

outcomes examined.

REFERENCES

1. Abbafati, C. *et al.* Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* **396**, 1204–1222 (2020).

2. Dieleman, J. L. *et al.* US Health Care Spending by Payer and Health Condition, 1996-2016. *JAMA* **323**, 863–884 (2020).

3. Whitty, C. J. M. *et al.* Rising to the challenge of multimorbidity. *The BMJ* vol. 368 (2020).

4. Uffelmann, E. *et al.* Genome-wide association studies. *Nat. Rev. Methods Prim.* **1**, 59 (2021).

5. Abdellaoui, A., Yengo, L., Verweij, K. J. H. H. & Visscher, P. M. 15 years of GWAS discovery: Realizing the promise. *Am. J. Hum. Genet.* **110**, 179–194 (2023).

6. Nelson, M. R. *et al.* The support of human genetic evidence for approved drug indications. *Nat. Genet.* **47**, 856–860 (2015).

7. King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. *PLOS Genet.* **15**, e1008489 (2019).

8. Yengo, L. *et al.* A saturated map of common genetic variants associated with human height. *Nature* **610**, 704–712 (2022).

9. Hartmann, S. *et al.* Genome-wide association study identifies ADRA2A and IRX1 as novel risk genes for Raynaud's phenomenon. *medRxiv* 2022.10.19.22281276 (2022) doi:10.1101/2022.10.19.22281276.

10. Bastarache, L. Using Phecodes for Research with the Electronic Health Record: From PheWAS to PheRS. *Annu. Rev. Biomed. Data Sci.* **4**, 1–19 (2021).

11. Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation. *JMIR Med. informatics* **7**, e14325 (2019).

12. Ghoussaini, M. *et al.* Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* **49**, D1311–D1320 (2021).

13. Mountjoy, E. *et al.* An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. *Nat. Genet.* **53**, 1527–1533 (2021).

14. Sollis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. *Nucleic Acids Res.* **51**, D977–D985 (2023).

15. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–518 (2023).

16. Hörer, S. *et al.* A Monoallelic Two-Hit Mechanism in PLCD1 Explains the Genetic Pathogenesis of Hereditary Trichilemmal Cyst Formation. *J. Invest. Dermatol.* **139**, 2154-2163.e5 (2019).

17. Hann, L. E., Hall, D. A., Black, E. B. & Ferrucci, J. T. Mittelschmerz. Sonographic demonstration. *JAMA* **241**, 2731–2 (1979).

18. Schall, P. Z., Ruebel, M. L., Midic, U., VandeVoort, C. A. & Latham, K. E. Temporal patterns of gene regulation and upstream regulators contributing to major developmental transitions during Rhesus macaque preimplantation development. *Mol. Hum. Reprod.* **25**, 111–123 (2019).

19. Zhang, J., Tomasini, A. J. & Mayer, A. N. RBM19 is essential for preimplantation

development in the mouse. *BMC Dev. Biol.* **8**, 115 (2008).

20.   Maurer, M. S. *et al.* Tafamidis Treatment for Patients with Transthyretin Amyloid
Cardiomyopathy. *N. Engl. J. Med.* **379**, 1007–1016 (2018).

21.   GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
human tissues. *Science* **369**, 1318–1330 (2020).

22.   Pietzner, M. *et al.* Mapping the proteo-genomic convergence of human diseases.
Science **374**, eabj1541 (2021).

23.   Chandak, P., Huang, K. & Zitnik, M. Building a knowledge graph to enable precision
medicine. *Sci. data* **10**, 67 (2023).

24.   Mahajan, M. C., Narlikar, G. J., Boyapaty, G., Kingston, R. E. & Weissman, S. M.
Heterogeneous nuclear ribonucleoprotein C1/C2, MeCP1, and SWI/SNF form a
chromatin remodeling complex at the beta-globin locus control region. *Proc. Natl.*
Acad. Sci. U. S. A. **102**, 15012–7 (2005).

25.   Uhlén, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**,
1260419 (2015).

26.   No Title. https://www.uniprot.org/uniprotkb/Q17RR3/entry
https://www.uniprot.org/uniprotkb/Q17RR3/entry (2023).

27.   Dajnoki, Z. *et al.* Sebaceous Gland-Rich Skin Is Characterized by TSLP Expression and
Distinct Immune Surveillance Which Is Disturbed in Rosacea. *J. Invest. Dermatol.* **137**,
1114–1125 (2017).

28.   Feofanova, E. V *et al.* A Genome-wide Association Study Discovers 46 Loci of the
Human Metabolome in the Hispanic Community Health Study/Study of Latinos. *Am. J.*
Hum. Genet. **107**, 849–863 (2020).

29.   Eraslan, G. *et al.* Single-nucleus cross-tissue molecular reference maps toward
understanding disease gene function. *Science* **376**, eabl4290 (2022).

30.   Pesantez-Cabrera, P. & Kalyanaraman, A. Detecting communities in biological
bipartite networks. *ACM-BCB 2016 - 7th ACM Conf. Bioinformatics, Comput. Biol.*
Heal. Informatics 98–107 (2016) doi:10.1145/2975167.2975177.

31.   Ravnborg, N. *et al.* Prevalence of asthma in patients with atopic dermatitis: A
systematic review and meta-analysis. *J. Am. Acad. Dermatol.* **84**, 471–478 (2021).

32.   Gallagher, A. *et al.* Anti-interleukin-13 and anti-interleukin-4 agents versus placebo,
anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. *Cochrane*
database Syst. Rev. **10**, CD012929 (2021).

33.   Williamson, E. J. *et al.* Factors associated with COVID-19-related death using
OpenSAFELY. *Nature* **584**, 430–436 (2020).

34.   The COVID-19 Host Genetics Initiative. A second update on mapping the human
genetic architecture of COVID-19. *medRxiv* **608**, 2022.12.24.22283874 (2022).

35.   Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequalae
of COVID-19. *Nature* **594**, (2021).

36.   Ochoa, D. *et al.* The next-generation Open Targets Platform: reimagined, redesigned,
rebuilt. *Nucleic Acids Res.* **51**, D1353–D1359 (2023).

37.   Licata, L. *et al.* SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update.
Nucleic Acids Res. **48**, D504–D510 (2020).

38.   Liu, Y.-J., Miao, H.-B., Lin, S. & Chen, Z. Association between rheumatoid arthritis and
thyroid dysfunction: A meta-analysis and systematic review. *Front. Endocrinol.*
(Lausanne). **13**, 1015516 (2022).

39.   Wu, D. *et al.* Graves' Disease and Rheumatoid Arthritis: A Bidirectional Mendelian

Randomization Study. *Front. Endocrinol. (Lausanne).* **12**, 1–9 (2021).

40.   Bliddal, S., Borresen, S. W. & Feldt-Rasmussen, U. Thyroid Autoimmunity and
Function after Treatment with Biological Antirheumatic Agents in Rheumatoid
Arthritis. *Front. Endocrinol. (Lausanne).* **8**, 179 (2017).

41.   Di Dalmazi, G., Chalan, P. & Caturegli, P. MYMD-1, a Novel Immunometabolic
Regulator, Ameliorates Autoimmune Thyroiditis via Suppression of Th1 Responses
and TNF-α Release. *J. Immunol.* **202**, 1350–1362 (2019).

42.   Wright, J. J., Powers, A. C. & Johnson, D. B. Endocrine toxicities of immune checkpoint
inhibitors. *Nat. Rev. Endocrinol.* **17**, 389–399 (2021).

43.   Köttgen, A. *et al.* Genome-wide association analyses identify 18 new loci associated
with serum urate concentrations. *Nat. Genet.* **45**, 145–54 (2013).

44.   Phipps-Green, A. J. *et al.* Twenty-eight loci that influence serum urate levels: analysis
of association with gout. *Ann. Rheum. Dis.* **75**, 124–30 (2016).

45.   Namba, S., Konuma, T., Wu, K. H., Zhou, W. & Okada, Y. A practical guideline of
genomics-driven drug discovery in the era of global biobank meta-analysis. *Cell*
Genomics **2**, 100190 (2022).

46.   Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery
across human disease. *Cell Genomics* **2**, (2022).

47.   Kemp, S. F., Fowlkes, J. L. & Thrailkill, K. M. Efficacy and safety of mecasermin
rinfabate. *Expert Opin. Biol. Ther.* **6**, 533–538 (2006).

48.   Gardner, E. J. *et al.* Damaging missense variants in IGF1R implicate a role for IGF-1
resistance in the etiology of type 2 diabetes. *Cell genomics* **2**, None (2022).

49.   Sapra, G. *et al.* The small-molecule BGP-15 protects against heart failure and atrial
fibrillation in mice. *Nat. Commun.* **5**, 5705 (2014).

50.   Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. *bioRxiv*
2020.08.10.244293 (2020) doi:10.1101/2020.08.10.244293.

51.   Cortes, A. *et al.* Bayesian analysis of genetic association across tree-structured routine
healthcare data in the UK Biobank. *Nat. Genet.* **49**, 1311–1318 (2017).

52.   Cortes, A., Albers, P. K., Dendrou, C. A., Fugger, L. & McVean, G. Identifying cross-
disease components of genetic risk across hospital data in the UK Biobank. *Nat.*
Genet. **52**, 126–134 (2020).

53.   Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in
complex traits. *Nat. Genet.* **51**, 1339–1348 (2019).

54.   Oussedik, E., Bourcier, M. & Tan, J. Psychosocial Burden and Other Impacts of
Rosacea on Patients' Quality of Life. *Dermatol. Clin.* **36**, 103–113 (2018).

55.   Baghad, B. *et al.* Pediatric Demodicosis Associated with Gain-of-Function Variant in
STAT1 Presenting as Rosacea-Type Rash. *J. Clin. Immunol.* **41**, 698–700 (2021).

56.   Deng, Z. *et al.* Keratinocyte-Immune Cell Crosstalk in a STAT1-Mediated Pathway:
Novel Insights Into Rosacea Pathogenesis. *Front. Immunol.* **12**, 1–13 (2021).

57.   van Zuuren, E. J. *et al.* Rosacea: New Concepts in Classification and Treatment. *Am. J.*
Clin. Dermatol. **22**, 457–465 (2021).

58.   Barrio-Hernandez, I. *et al.* Network expansion of genetic associations defines a
pleiotropy map of human cell biology. *Nat. Genet.* (2023) doi:10.1038/s41588-023-
01327-9.

59.   MacNamara, A. *et al.* Network and pathway expansion of genetic disease associations
identifies successful drug targets. *Sci. Rep.* **10**, (2020).

60.   Marigorta, U. M., Rodríguez, J. A., Gibson, G. & Navarro, A. Replicability and

Prediction: Lessons and Challenges from GWAS. *Trends Genet.* **34**, 504–517 (2018).

61.   Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a
wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779
(2015).

62.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
Nature **562**, 203–209 (2018).

63.   Denaxas, S. Mapping the Read2/CTV3 controlled clinical terminologies to Phecodes in
UK Biobank primary care electronic health records: implementation and evaluation.
Proc. Am. Med. Informatics Assoc. Annu. Symp. 2021 (2021).

64.   Mbatchou, J. *et al.* Computationally efficient whole-genome regression for
quantitative and binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).

65.   Bulik-sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
polygenicity in genome-wide association studies. *Nat. Publ. Gr.* **47**, (2015).

66.   Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to
variable selection in regression, with application to genetic fine mapping. *J. R. Stat.*
Soc. Ser. B Stat. Methodol. **82**, 1273–1300 (2020).

67.   Wakefield, J. Bayes Factors for Genome-Wide Association Studies : Comparison with P
-values. **86**, 79–86 (2009).

68.   Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
Association Studies Using Summary Statistics. *PLoS Genet.* **10**, (2014).

69.   Wallace, C. Eliciting priors and relaxing the single causal variant assumption in
colocalisation analyses. *PLoS Genet.* **16**, 1–20 (2020).

70.   Discover., C. I. (n. d.). C. Cell. No Title. *Retrieved (20/01/2023), from*
https://cellxgene.cziscience.com/.

71.   Shannon, P. *et al.* Cytoscape: a software environment for integrated models of
biomolecular interaction networks. *Genome Res.* **13**, 2498–504 (2003).

72.   Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal
pleiotropy in causal relationships inferred from Mendelian randomization between
complex traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).

73.   COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of
COVID-19. *Nature* **600**, 472–477 (2021).

74.   Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing
Mendelian randomization analyses using summarized data. *Int. J. Epidemiol.* **46**,
1734–1739 (2017).

75.   Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across
the human phenome. *Elife* **7**, (2018).

76.   Wallace, C. A more accurate method for colocalisation analysis allowing for multiple
causal variants. *PLoS Genet.* **17**, e1009440 (2021).

77.   Zou, Y., Carbonetto, P., Wang, G. & Stephens, M. Fine-mapping from summary data
with the " Sum of Single Effects " model. 1–33 (2021).